A Phase 1 Study of MLN518 Given in Combination With Standard Induction Chemotherapy for the Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Trial Profile

A Phase 1 Study of MLN518 Given in Combination With Standard Induction Chemotherapy for the Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2008

At a glance

  • Drugs Cytarabine; Daunorubicin; Tandutinib
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Millennium
  • Most Recent Events

    • 08 Feb 2008 Status change from in progress to completed, from clinicaltrials.gov record.
    • 12 Jul 2007 Status changed from recruiting to in progress.
    • 09 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top